Business Context and Reporting Period
Karyopharm Therapeutics Inc. filed a Form 8-K on February 27, 2026, reporting the entry into a Second Amendment to its Credit and Guaranty Agreement and a Forbearance Agreement. The company is a biopharmaceutical firm focused on the commercialization of XPOVIO and the development of drug candidates, including selinexor. The filing addresses liquidity management to extend the company's runway beyond the second quarter of 2026 and past the anticipated mid-2026 reporting of top-line data from the Phase 3 XPORT-EC 042 trial.
Key Financial Metrics and Agreements
- Capital Raise Trigger: The agreements are conditioned on the company raising at least $25.0 million in cash proceeds from the sale of common stock before June 10, 2026.
- Liquidity Covenant: The minimum consolidated liquidity covenant is maintained at $10.0 million through October 10, 2026, provided the Capital Raise Trigger is met. After this date, the requirement increases to $25.0 million.
- Payment Deferrals: If the Capital Raise Trigger is met, the cash interest payment due June 30, 2026, will be paid in kind, and the principal installment due June 10, 2026, will be deferred to September 10, 2026.
- Prepayment Premium: A 5% prepayment premium applies through June 10, 2026. If the Capital Raise Trigger occurs, this premium extends through May 8, 2027.
- Debt Instruments: The Forbearance Agreement involves 100% of lenders under the Credit Agreement, holders of 9.00% Convertible Senior Notes due 2028 and 2029, and investors under the revenue interest financing agreement.
Material Changes Versus Prior Period
The filing represents a material change in the company's debt structure and covenant requirements compared to the original Credit Agreement dated May 8, 2024. Key modifications include:
- Exclusion of proceeds from the Capital Raise Trigger from the calculation of the minimum liquidity covenant, preventing an automatic increase in the liquidity threshold upon raising funds.
- Extension of the forbearance period for payment-related defaults until September 30, 2026, and for liquidity-related defaults until October 10, 2026.
- Modification of the prepayment premium schedule contingent on the successful capital raise.
Guidance, Outlook, and Risks
Management expects the amendments to reduce the capital required to extend the liquidity runway beyond the second quarter of 2026. The company anticipates reporting top-line data from the Phase 3 XPORT-EC 042 trial in mid-2026. However, the filing includes significant risk disclosures:
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern.
- Conditional Effectiveness: The Forbearance Agreement is not effective unless the Capital Raise Trigger ($25.0 million) is met.
- Commercial and Clinical Risks: Risks include the adoption of XPOVIO, regulatory approvals, clinical trial results, and the ability to enroll patients.
- Market Risks: There is no guarantee that positive developments will result in stock price appreciation.
Investor Verification Checklist
- Verify whether the company has successfully raised the required $25.0 million in cash proceeds before June 10, 2026, to trigger the payment deferrals and covenant relief.
- Monitor the company's cash balance to ensure compliance with the $10.0 million minimum liquidity covenant through October 10, 2026.
- Review the timing and results of the Phase 3 XPORT-EC 042 trial, expected in mid-2026, as a critical catalyst for future funding and commercialization.
- Assess the status of the Forbearance Agreement and whether any termination events have occurred that would allow lenders to exercise remedies.
- Examine the company's cash burn rate and any unplanned expenditures that could impact the liquidity runway.